Search - tctmd.com

Displaying 61 - 68 of 68

Sort: Relevancy | Date

News Daily News

Ten Principles for Successful Treatment of HF With Reduced EF: New ACC Decision Pathway

Michael O'Riordan

January 02, 2018

News Daily News

Generic ARBs Linked to Increased Adverse Events

Michael O'Riordan

October 04, 2017

News Conference News ACC 2017

Many Patients Prescribed PCSK9 Inhibitors Never End Up Getting Them

Yael L. Maxwell

March 23, 2017

News Features

全年回顾：医生选出介入心脏病学等领域 2016 年的最大新闻

Shelley Wood

December 30, 2016

News Daily News

La FDA Aprueba un Fármaco contra la Insuficiencia Cardíaca que Beneficia la Supervivenia

Todd Neale

July 13, 2015

News Daily News

FDA批准了一种具有生存优势的心力衰竭药物

Todd Neale

July 13, 2015

News Daily News

FDA Approves Heart Failure Drug That Comes With Survival Benefit

Todd Neale

July 13, 2015

News Industry News

Novartis' new heart failure medicine LCZ696 approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization; now called Entresto™ (sacubitril-valsartan)

July 07, 2015

Advertisement

Ten Principles for Successful Treatment of HF With Reduced EF: New ACC Decision Pathway

Generic ARBs Linked to Increased Adverse Events

Many Patients Prescribed PCSK9 Inhibitors Never End Up Getting Them

全年回顾：医生选出介入心脏病学等领域 2016 年的最大新闻

La FDA Aprueba un Fármaco contra la Insuficiencia Cardíaca que Beneficia la Supervivenia

FDA批准了一种具有生存优势的心力衰竭药物

FDA Approves Heart Failure Drug That Comes With Survival Benefit

Novartis' new heart failure medicine LCZ696 approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization; now called Entresto™ (sacubitril-valsartan)

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content